Surgical Management of the Axilla in Breast Cancer Patients with Negative Sentinel Lymph Node: A Method to Reduce False-Negative Rate
- 58 Downloads
False-negative rate (FNR) of sentinel lymph node dissection (SLND) has not been eliminated. The study was conducted to optimize the surgical resection of axilla in patients with negative sentinel lymph node (SLN) for the purpose of eradicating false-negative (FN) events of SLND.
A total of 312 clinically node-negative patients without neoadjuvant therapy underwent SLND with indocyanine green (ICG), methylene blue and the combination of ICG and methylene blue. Axillary dissection was performed subsequently regardless of the status of SLN. Lymph nodes were sent for pathological examination separately by serial resection every 0.5 cm away from marginally visualized SLNs.
SLND was successfully conducted in 98.1% (306/312) of patients using methylene blue, ICG, and its combination. Further examination revealed 97 true-positive, 189 true-negative, and 13 FN results. The overall FNR was 11.8% (13/110). A horizontal line 1.5 cm away from the superior vSLN and a vertical line 1.5 cm away from the medial vSLN formed a zone of lower outer quadrant (LOQ) in axilla. Surgical resection of LOQ ‘en bloc’ showed a FNR of zero.
The surgical management of axilla may benefit negative SLN patients with potential nodal involvement, reducing the FNR of SLND to zero.
Trial registration number and agency
This study was registered with the Chinese Clinical Trial Registry (ChiCTR1800014247).
The authors thank the studied patients for their willingness to cooperate with our study.
Compliance with ethical standards
Conflict of interest
All the authors report no conflict of interest.
- 4.Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888CrossRefGoogle Scholar
- 6.Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933CrossRefGoogle Scholar
- 14.Boughey JC, Ballman KV, Le-Petross HT et al (2016) Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy. Ann Surg 263:802–807CrossRefGoogle Scholar
- 25.van der Vorst JR, Schaafsma BE, Verbeek FPR et al (2012) Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99 m technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. Ann Surg Oncol 19:4104–4111CrossRefGoogle Scholar